背景:本研究旨在评估在德国口腔颌面外科中使用肉毒杆菌毒素(BTX)治疗磨牙症的方法。
方法:制定了包含7至25个问题的动态在线问卷,以收集有关使用BTX治疗磨牙症的一般和具体信息。问卷经过内部和外部评估以进行验证。随后,它已分发给隶属于德国口腔颌面外科协会(DGMKG)的906名口腔颌面外科医师(OMFS)。在四周内每周发出提醒,以提高回应率。参与研究是自愿和匿名的。采用描述性方法进行数据分析。
结果:107OMFS参与了这项研究,产生11.81%的应答率。平均而言,每月有17例磨牙症患者,其中4例患者接受BTX治疗。BTX给药经常伴随着夹板和物理治疗(35.51%的参与者)。Botox®(Allergan)是首选的BTX制剂,40.79%的参与者利用,92.11%的参与者用盐水重建。咬肌主要用于BTX治疗(67.57%的参与者),平均每侧29个BTX(Allergan-)单位。每个咬肌的注射点通常为每侧六个,30.67%的参与者首选。定期进行BTX治疗后的随访评估,主要是四周后,36%的参与者。在8%的案例中,由于结局不足,需要额外注射BTX.4%的病例报告有副作用,通常表现为咬合力的非干扰性降低。使用BTX进行磨牙症治疗的大多数参与OMFS(61.84%)将BTX进行磨牙症治疗视为循证。值得注意的是,97.37%的受访者表示愿意向同事推荐基于BTX的磨牙症治疗。总的来说,BTX治疗磨牙症的疗效分别为良好(53.95%)和非常好(40.79%).
结论:德国在OMFS中使用BTX治疗磨牙症已证明有效。已观察到使用BTX治疗磨牙症的某些方面存在实质性差异。
结论:有必要进行更多的研究,以全面调查BTX治疗磨牙症的不同因素,包括BTX单位的最佳剂量和各种肌肉注射部位的精确定位。
BACKGROUND: This study aimed to evaluate the use of botulinum toxin (BTX) for the treatment of
bruxism in oral and maxillofacial surgery in Germany.
METHODS: A dynamic online questionnaire comprising 7 to 25 questions was formulated to gather general and specific information regarding using BTX to treat
bruxism. The questionnaire underwent internal and external assessments for validation. Subsequently, it was distributed to 906 oral and maxillofacial surgeons (OMFS) affiliated with the German Association for Oral and Maxillofacial Surgery (DGMKG). Weekly reminders were dispatched over four weeks to enhance response rates. Participation in the study was voluntary and anonymized. Descriptive methods were employed for data analysis.
RESULTS: 107 OMFS participated in the study, yielding a response rate of 11.81%. On average, 17 patients with
bruxism were per month, with 4 of these patients receiving BTX therapy. BTX administration was frequently accompanied by splints and physiotherapy (35.51% of participants). Botox® (Allergan) was the preferred BTX preparation, utilized by 40.79% and reconstituted with saline by 92.11% of participants. The masseter muscles were primarily targeted for BTX treatment (67.57% of participants), averaging 29 BTX (Allergan-) units per side. Injection points for each masseter muscle typically amounted to six per side, preferred by 30.67% of participants. Follow-up assessments post-BTX treatment were conducted regularly, predominantly after four weeks, by 36% of participants. In 8% of cases, additional BTX injections were necessary due to inadequate outcomes. Side effects were reported in 4% of cases, commonly manifesting as a non-disturbing reduction in bite force. Most participating OMFS (61.84%) using BTX for
bruxism therapy regarded
bruxism treatment with BTX as evidence-based. Notably, 97.37% of respondents expressed their willingness to recommend BTX-based bruxism treatment to their colleagues. Overall, the efficacy of BTX therapy for bruxism was rated as good (53.95%) and very good (40.79%).
CONCLUSIONS: The use of BTX for the management of bruxism among OMFS in Germany has demonstrated efficacy. Substantial variances in certain facets of
bruxism treatment employing BTX have been observed.
CONCLUSIONS: Additional research endeavors are warranted to comprehensively investigate distinct elements of BTX therapy for bruxism, including the optimal dosage of BTX units and the precise localization of injection sites across various muscles.